Academic-Industry Partnership Symposium

Presented by: Blank Rome LLP

The mission of PhIND is to create a collaborative research organization that attracts excellent scientists, accelerates

the pace of research on neurodegenerative disorders, and establishes a leading, internationally-recognized center of

Neuroscience discovery and development.

Panel Members

• Todd Abrams, PhD – BioStrategy Partners• Gordon Lutz, PhD – LifeSplice Pharma, LLC• Stephen Nappi – Temple University• David Gitlin, Esq. – Blank Rome LLP• Ezra Felker – Nupathe Inc.• John Reid, PhD, MBA – AstraZeneca

Barriers to CollaborationEcosystem member Member associated barriers

Principal Investigator/ Inventor • Not interested in performing industry focused experiments (Identified by Industry)

• Not informed about IP and commercialization (identified by Industry and TTO)

• PI signs agreements (identified by TTO)• No promotions for inventing (traditional barrier)• Management and urgency of data (Identified by Industry)

Technology Transfer Office • Lack of resources for IP and commercialization (TTO barrier)

• Multiple offices review documents (TTO barrier)• Mismatch of expectations (traditional Industry barrier)• Patent Policy not considered legally binding by PI (PI

identified)

Barriers to CollaborationEcosystem member Member associated barriers

Legal • Research agreements aligned to one side or the other due to legal representative (traditional barrier)

• Long review and over-engineered documents (general comment)

Solution Academia associated barriers

• Third parties assist TTO and investigator to explain commercialization issues• Legal informs investigator IP policy is binding and no agreements outside University are

permitted• Develop common agreements with compromise language

• Sets expectations. • Permits focus on the commercialization plan• Reduces legal review time

Barriers to CollaborationEcosystem member Member associated barriers

Biotech and Pharmaceutical Industry

• Intellectual Property rights for improvement and related inventions (self identified, TTO and Legal)

• ROI and academic expectations do not match (general barrier)

• On time on budget (i.e. urgency of data) (for TTO and PI)

Solution industry barriers

• Reward all innovation through planned co-development• Match investment with results• Make sure termination provisions are comprehensive

New Models of Collaboration• “Drug discovery on campus” one to one industry to

University relationships with a new purpose• Disease focus interest groups model (PhIND, Philly Derm) • Consortium Model • Regional technology exchange (Science Center – QED)• Example models: Coulter; MaRS District, CPATHNew Barriers: New purpose of research;

Complex agreements including financial, IP, operations and governance issues different from sponsored research

New Models of Collaboration• Key points of Discussion:– Agreements some proprietary information such as compounds

and targets not shared– Shared resource opportunities– Follow on research milestone based to reward success– Avoid IP argument by company having license to IP and data

related to company compounds– Provisions to rewards academic innovation – Key to success: dedicated project and alliance management

Q & Adfa

Thank you for your support!

www.PhINDResearch.org